Skip to main content
. 2022 Jan 21;10(3):899–918. doi: 10.12998/wjcc.v10.i3.899

Table 6.

Diagnostic characteristics of carcinoembryonic antigen, carbohydrate antigen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index

Parameters
Se
Sp
PPV
NPV
CUI-(Ve+)
CUI-(Ve-)
FC
CEA 86.9 (78.4-95.4) 79.7 (73.1-86.3) 64.6 (54.3-75.0) 93.4 (89.1-97.8) 0.561 (0.44-0.68) 0.752 (0.64-0.80) 81.94
CA19-9 80.6 (67.6-95.5) 72.5 (62.7-82.3) 56.9 (43.3-70.5) 89.2 (81.7-96.8) 0.46 (0.29-0.63) 0.652 (0.57-0.73) 753
NLR 68.8 (53.2-84.0) 66.7 (56.4-76.9) 47.1 (33.4-60.8) 83.1 (74.0-92.2) 0.32 (0.14-0.50) 0.551 (0.46-0.64) 67.2
PLR 53.8 (34.7-73.1) 81.3 (67.7-94.8) 70.0 (49.9-90.1) 68.4 (53.6-83-2) 0.38 (0.13-0.62) 0.551 (0.43-0.68) 69
CII 70.3 (55.5-85.0) 65.9 (55.6-76.1) 48.1 (34.8-61.5) 83.1 (74.0-97.2) 0.34 (0.16-0.50) 0.551 (0.46-0.64) 67.2
1

Satisfactory/adequate clinical utility index (CUI).

2

Good CUI.

3

Overall utility satisfactory/adequate.

4

Overall utility good. A qualitative interpretation of the clinical utility index: (E) ≥ 0.81 excellent; (G) ≥ 0.64 good; (SA) ≥ 0.49 satisfactory/adequate; (P) ≥ 0.36 poor; (VP) < 0.36 very poor. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; CUI+: Clinical utility index positive; CUI-: Clinical utility index negative; FC: Fraction correct; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.